Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adenocarcinoma × ipatasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 13 Ovarian Neoplasms 5 Neoplasms 5 Triple Negative Breast Neoplasms 4 Prostatic Neoplasms 4 Neoplasm Metastasis 4 Carcinoma, Non-Small-Cell Lung 3 Stomach Neoplasms 2 Solid Tumors 2 Mouth Neoplasms 2 Laryngeal Neoplasms 2 Hypopharyngeal Neoplasms 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Endometrial Neoplasms 2 Carcinoma 2 Squamous Cell Carcinoma of Head and Neck 1 Solid Cancers 1 Skin Diseases 1 Recurrence 1 Oropharyngeal Neoplasms 1 Neoplasms by Site 1 Gliosarcoma 1 Gastrointestinal Neoplasms 1 Breast Diseases 1 Adenocarcinoma 1

Interventions

Oxaliplatin 42 Gemcitabine 40 Fluorouracil 36 Capecitabine 29 pembrolizumab 25 Leucovorin 25 Docetaxel 25 Cisplatin 23 Paclitaxel 19 Carboplatin 17 Bevacizumab 16 130-nm albumin-bound paclitaxel 15 Pemetrexed 14 Irinotecan 14 Radiotherapy 13 Albumin-Bound Paclitaxel 12 Nivolumab 10 Ramucirumab 9 Cyclophosphamide 9 Trastuzumab 7 Radiosurgery 7 cemiplimab 6 Erlotinib Hydrochloride 6 Drug Therapy 6 zolbetuximab 5 trastuzumab deruxtecan 5 durvalumab 5 Taxes 5 Sorafenib 5 S 1 (combination) 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04739202 2021-03-29

IMMUNOGAST

Hospices Civils de Lyon

Phase 2 Unknown

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡